US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’

 
• By Sue Sutter
  
Gavel and decisionmaker
Acting Commissioner Sara Brenner ended Vanda's bid to add an insomnia indication to the Hetlioz label. (Shutterstock)

More from Approval Standards

More from Product Reviews